Answers are grounded in this paper and cite their sources.
= 557.6 μM) with high selectivity index (308.4) against SARS-CoV-2 in Vero E6 cells. This work may clarify and approve not only the safety of ARBs used by a large group of patients worldwide but also their possible effectiveness against the COVID-19 virus either as a prophylactic or treatment option. It intended also to give a clear spot on the structure-activity relationship (SAR) required for the future design of new drugs targeting the newly emerged SARS-CoV-2 protease by medicinal chemists.
No takes yet. Share an insight, caveat, or question.
Alnajjar et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: